NASDAQ:CADX - Cadence Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cadence Pharmaceuticals logoCadence Pharmaceuticals, Inc. (Cadence) is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing products principally for use in the hospital setting. The Company has rights to one product, OFIRMEV (acetaminophen) injection, an intravenous (IV), formulation of acetaminophen. The Company in-licensed the United States, and Canadian rights to OFIRMEV from Bristol-Myers Squibb Company (BMS), which sells intravenous acetaminophen in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. In March 2014, Mallinckrodt Plc acquired Cadence Pharmaceuticals, Inc. In March 2014, Mallinckrodt Plc completed the acquisition of Cadence Pharmaceuticals.

Receive CADX News and Ratings via Email

Sign-up to receive the latest news and ratings for CADX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
SymbolNASDAQ:CADX
CUSIP12738T10
Phone+1-858-4361400

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00

The Truth About Cryptocurrencies

Cadence Pharmaceuticals (NASDAQ:CADX) Frequently Asked Questions

What is Cadence Pharmaceuticals' stock symbol?

Cadence Pharmaceuticals trades on the NASDAQ under the ticker symbol "CADX."

What is the consensus analysts' recommendation for Cadence Pharmaceuticals?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cadence Pharmaceuticals in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Has Cadence Pharmaceuticals been receiving favorable news coverage?

Media headlines about CADX stock have trended somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cadence Pharmaceuticals earned a media sentiment score of 0.09 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 48.13 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.

How do I buy shares of Cadence Pharmaceuticals?

Shares of CADX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Cadence Pharmaceuticals?

Cadence Pharmaceuticals' mailing address is 12481 High Bluff Dr Ste 200, SAN DIEGO, CA 92130-3583, United States. The biopharmaceutical company can be reached via phone at +1-858-4361400.


MarketBeat Community Rating for Cadence Pharmaceuticals (NASDAQ CADX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  112 (Vote Outperform)
Underperform Votes:  102 (Vote Underperform)
Total Votes:  214
MarketBeat's community ratings are surveys of what our community members think about Cadence Pharmaceuticals and other stocks. Vote "Outperform" if you believe CADX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CADX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Featured Article: Closed-End Mutual Funds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.